All In Biotech

Drug Trial Radar · NCT06164327

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Multicenter, Open Phase Ib Study of the Safety and Efficacy of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

75

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

Oct 31, 2025

Study completion Nov 5, 2025

Sponsor

Lead sponsor
BeBetter Med IncIndustry
Sponsor type
Industry
First posted
Dec 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open Phase Ib clinical study to evaluate the safety,efficacy and pharmacokinetics of BEBT-908 combined with Rituximab (R) or combined with Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) or combined with Rituximab-Ifosfamide-Carboplatin-Etoposide (R-ICE) in the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

Conditions

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions

  • BEBT-908 for InjectionDrug

    BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2,frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.

  • Rituximab InjectionDrug

    Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.

  • Gemcitabine Hydrochloride for InjectionDrug

    Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.

  • Oxaliplatin InjectionDrug

    Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.

  • Etoposide InjectionDrug

    Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.

  • Ifosfamide for InjectionDrug

    Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.

  • Carboplatin InjectionDrug

    Carboplatin Injection,dosage of administration:based on AUC=5, single dose ≤800 mg,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Every 6 weeks,assessed up to 24 months.
  2. AETime frame: From the first administration of the study drug to 28 days after the last administration of the study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.